Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine.
San Francisco Department of Public Health.
Psychol Addict Behav. 2020 Feb;34(1):23-30. doi: 10.1037/adb0000504. Epub 2019 Aug 22.
Substance use can interfere with HIV treatment. A previous multisite clinical trial (Metsch et al., 2016) tested 2 behavioral interventions designed to improve treatment engagement in people with comorbid HIV and drug or heavy alcohol use. Clinical trial participants were randomized to treatment as usual (N = 264), patient navigation (PN; N = 266), or PN with contingency management (PN + CM; N = 271) for 6 months. PN + CM patients could earn financial incentives both for entering substance use disorder (SUD) treatment and for submitting urine and breath samples negative for opioids, stimulants, and alcohol. This secondary analysis compared frequencies of treatment entry and sample submission in the PN versus PN + CM groups and examined associations with viral suppression (defined as ≤200 copies/mL). Incentives were associated with a higher percentage of patients entering SUD treatment (PN = 25.5%; PN + CM = 47.6%; p < .001), a higher percentage submitting samples for drug testing (PN median = 2, interquartile range [IQR] = 0.5; PN + CM median = 8, IQR = 5.1; p < .0001) and a higher percentage submitting samples negative for targeted drugs and alcohol (PN median = 1, IQR = 0.3; PN + CM median = 6, IQR = 2.9; p < .0001). Within the PN + CM group, up to 58% of those with high rates of engagement in activities were virally suppressed at 6 months versus 24-29% in subgroups with lowest engagement. In conclusion, CM was feasibly incorporated into PN for persons with HIV and SUD and was associated with higher rates of engagement in targeted substance use abatement activities. CM has the potential to improve health outcomes in this population. (PsycINFO Database Record (c) 2020 APA, all rights reserved).
物质使用会干扰 HIV 治疗。先前的多地点临床试验(Metsch 等人,2016)测试了 2 种旨在改善合并 HIV 和药物或大量饮酒的人治疗参与度的行为干预措施。临床试验参与者被随机分配至常规治疗(N=264)、患者导航(PN;N=266)或 PN 加条件管理(PN+CM;N=271)治疗 6 个月。PN+CM 患者可以因进入物质使用障碍(SUD)治疗和提交尿液和呼吸样本呈阿片类、兴奋剂和酒精阴性而获得财务奖励。这项二次分析比较了 PN 与 PN+CM 组的治疗进入和样本提交频率,并检查了与病毒抑制(定义为 ≤200 拷贝/ml)的关联。奖励与更多的患者进入 SUD 治疗(PN=25.5%;PN+CM=47.6%;p<.001)、更多的药物测试样本提交(PN 中位数=2,四分位距 [IQR]=0.5;PN+CM 中位数=8,IQR=5.1;p<.0001)和更多的目标药物和酒精阴性样本提交(PN 中位数=1,IQR=0.3;PN+CM 中位数=6,IQR=2.9;p<.0001)相关。在 PN+CM 组中,高达 58%的高活动参与率患者在 6 个月时病毒得到抑制,而在活动参与率最低的亚组中,这一比例为 24-29%。总之,CM 可切实融入 HIV 和 SUD 患者的 PN 中,与目标物质使用减少活动的更高参与率相关。CM 有可能改善这一人群的健康结果。(PsycINFO 数据库记录(c)2020 APA,保留所有权利)。